The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. METHODS: We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety. RESULTS: At a median follow-up of 65 months, 656 events triggered this protocol-specified analysis. The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 91%, respectively. No significant differences in efficacy (disease-free or overall survival) were found between the two trastuzumab regimens, whereas both were superior to AC-T. The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups receiving the anthracycline-based regimens and one in the TCH group subsequent to receiving an anthracycline outside the study. CONCLUSIONS: The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials.gov number, NCT00021255.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
RetractedSlamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Research works printed but not linked: 7
- Arboleda MJ, 2003, Cancer Res, 63, 196
- Pietras RJ, 1995, Oncogene, 10, 2435
- Hancock MC, 1991, Cancer Res, 51, 4575
- Pegram MD, 1999, Semin Oncol, 26, 89
- Pietras RJ, 1994, Oncogene, 9, 1829
- 10.1200/JCO.2005.11.012 · doi:10.1200/jco.2005.11.012
- 10.1093/jnci/90.18.1361 · doi:10.1093/jnci/90.18.1361
Cited by
Items 101–114 of 114
Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
Gu, G., Dustin, D., & Fuqua, S. A. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.11.005 · Cited by 163
Minuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127
Hurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2294 · Cited by 115
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3628 · Cited by 99
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Triulzi, T., Regondi, V., De Cecco, L., Cappelletti, M. R., Di Modica, M., Paolini, B., Lollini, P. L., Di Cosimo, S., Sfondrini, L., Generali, D., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0318-0 · Cited by 94
“Treatment with trastuzumab and chemotherapy has dramatically changed the prognosis of early and advanced HER2-positive (HER2+) BC patients.(1) More recently, the introduction and availability of other HER2-targeting agents offer clinicians the ability to provide prolonged inhibition of HER2 signalling across multiple…”
BackgroundNeurological sequelae of cancer immunotherapies and targeted therapies
Wick, W., Hertenstein, A., & Platten, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30571-x · Cited by 87
Pivot, X., Spano, J. P., Espie, M., Cottu, P., Jouannaud, C., Pottier, V., Moreau, L., Extra, J. M., Lortholary, A., Rivera, P., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.009 · Cited by 70
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Forterre, A. V., Wang, J.-H., Delcayre, A., Kim, K., Green, C., Pegram, M. D., Jeffrey, S. S., & Matin, A. C. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0928 · Cited by 62
A Multimodal Knowledge-enhanced Whole-slide Pathology Foundation Model
Xu, Y., Wang, Y., Zhou, F., Ma, J., Jin, C., Yang, S., Li, J., Zhang, Z., Zhao, C., Zhou, H., et al. (2024) · arXiv · doi:10.48550/arxiv.2407.15362 · Cited by 60
Hedayati, E., Fracheboud, L., Srikant, V., Greber, D., Wallberg, S., & Linder Stragliotto, C. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211783 · Cited by 39
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
Khalifa, S. E., & Fathy, Y. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.318 · Cited by 20
Metadata
- Authors
- Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., Pinter, T., Valero, V., Liu, M.-C., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., Tabah-Fisch, I., Lindsay, M.-A., Riva, A., & Crown, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-10-06
- Volume
- 365
- Issue
- 14
- Pages
- 1273-1283
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098775844
- Cited by
- 2,775
- References
- 42
- FWCI
- 76.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.